Enrolling Clinical Trials: Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer - Penn Medicine
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer - European Journal of Cancer
Enrolling Clinical Trials: Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer - Penn Physician VideoLink
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis | Scientific Reports
Breakthrough from PAOLA1 GINECO/ENgOT-ov25 trial
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)☆ - ESMO Open
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evid | OTT
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis - Gynecologic Oncology
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
Clinical Trials of PARP inhibitors in ovarian cancer | Download Table
SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer | Business Wire
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer - Annals of Oncology
PARP inhibitors: Choosing what to use in epithelial ovarian cancer
Blockbuster status competition intensifying for PARP inhibitors - Pharmaceutical Technology
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design | Future Oncology
PAOLA-1 Phase 3 Trial – LYNPARZA® (olaparib) + Bevacizumab for Advanced Ovarian Cancer
Clinical trials results for PARP Inhibitors in ovarian cancer. | Download Table
3 Charts | Olaparib: A New Hope for BRCA Patients with Ovarian Cancer
SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer
JCM | Free Full-Text | Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study | HTML
Lynparza (olaparib) for the Treatment of BRCA-mutated Advanced Ovarian Cancer - Clinical Trials Arena
Olaparib for Ovarian Cancer Clinical Trial | Power
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial - ScienceDirect
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
